IMMEDICA PHARMA is a pharmaceutical company focused on Neurology, Oncology. Key products include ZTALMY.
FDA Novel Drug Designations
(2022)See 1 novel approval →
IMMEDICA PHARMA's Key Drugs
IMMEDICA PHARMA's core commercial portfolio centers on ZTALMY, spanning Neurology and Oncology — its most strategically important drugs approved in the last 15 years.
IMMEDICA PHARMA's Recent FDA Approvals
New NDA/BLA approvals for IMMEDICA PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
IMMEDICA PHARMA's Therapeutic Areas
IMMEDICA PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IMMEDICA PHARMA's Top Competitors
IMMEDICA PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IMMEDICA PHARMA Pipeline Snapshot
IMMEDICA PHARMA has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZTALMY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-03-18
- Latest
- 2025-10-16
- Applications
- 1